NEW
YORK, May 23, 2022 /PRNewswire/ -- Mind
Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) (the
"Company" or "MindMed"), a clinical stage biopharmaceutical company
developing novel products to treat brain health disorders,
announced the appointment of Schond L. Greenway as Chief Financial
Officer. Mr. Greenway comes to MindMed with over 20 years of
experience in investment banking, finance and corporate advisory,
and investment analysis in the life sciences sector.
![Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed)) Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))](https://mma.prnewswire.com/media/996320/Mindmed_Logo.jpg)
"We are very excited to add Schond to our management team.
Schond brings extensive expertise in US biotech capital markets,
which was a key attribute we sought in identifying a CFO," said
Robert Barrow, Chief Executive
Officer and Director of MindMed. "Schond is joining MindMed at an
exciting point in our growth, with numerous near-term milestones
ahead across our pipeline. I look forward to working closely with
him to advance our mission of becoming a global leader in the
development of innovative therapies for brain health
disorders."
"This is an exciting time to be joining the Company as it
continues its patient-focused mission of developing innovative new
therapies to improve outcomes for individuals with anxiety,
addiction and autism," said Mr. Greenway. "I'm excited to join this
dynamic and talented team. I look forward to working with the
management team to advance the Company's robust pipeline and
contribute to its success."
Mr. Greenway joins MindMed after serving as CFO of Avalo
Therapeutics, a precision medicine clinical stage biopharmaceutical
company. He previously served as VP of Investor Relations at
Mesoblast, an allogeneic cellular medicines company. He served in a
similar role at Halozyme Therapeutics, Inc. and in various roles at
investment banking firms Morgan Stanley and Barclays Capital,
predominantly focused on healthcare and technology. Mr. Greenway
has participated in and advised on numerous transactions during his
tenure in investment banking and capital markets. He has assisted
in securing significant cumulative growth capital through a variety
of equity and debt instruments in the public and private markets,
as well as through funding from significant collaboration
arrangements with therapeutics companies.
Mr. Greenway received an MBA from the Darden Graduate School of
Business – University of Virginia and a
BS from Florida A&M University.
About MindMed
MindMed is a clinical stage
biopharmaceutical company developing novel products to treat brain
health disorders, with a particular focus on psychiatry, addiction,
pain and neurology. Our mission is to be the global leader in the
development and delivery of treatments that unlock new
opportunities to improve patient outcomes. We are developing a
pipeline of innovative drug candidates, with and without acute
perceptual effects, targeting the serotonin, dopamine and
acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
For Media: media@mindmed.co
For Investors: ir@mindmed.co
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-appoints-schond-l-greenway-as-chief-financial-officer-301552598.html
SOURCE Mind Medicine (MindMed) Inc.